Skip to main content

Advertisement

Figure 4 | Journal of Translational Medicine

Figure 4

From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Figure 4

Progression-free survival and overall survival in all enrolled patients. (a) Progression-free survival after 1st vaccination. The MST was 3.4 months and the 1-year PFS ratio was 11.1%. (b) Overall survival after the 1st vaccination. The MST was 9.7 months and the 1-year OS ratio was 22.2%. (c) Overall survival of the patients with Grade 2 ISR (solid line) compared to that of the patients with Grade 1 ISR (dotted line). There was a statistically significant difference between these 2 groups (p = 0.003). (d) Overall survival of the patients receiving continuous vaccination (solid line) compared to that of the patients who stopped the vaccination at the determination of PD (dotted line). There was a statistically significant difference between these 2 groups (p = 0.007).

Back to article page